Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004912|
Recruitment Status : Completed
First Posted : March 3, 2004
Last Update Posted : May 30, 2012
RATIONALE: Megestrol helps improve appetite. Exercise may decrease cancer-related fatigue, improve strength, and build up lost muscle tissue. Exercise plus megestrol may be effective treatment for cancer-related weight loss.
PURPOSE: Phase II trial to study the effectiveness of megestrol plus exercise to improve appetite, increase strength, gain lean body tissue, and decrease fatigue in patients who have cancer-related weight loss.
|Condition or disease||Intervention/treatment||Phase|
|Cachexia Fatigue Unspecified Adult Solid Tumor, Protocol Specific||Drug: megestrol acetate Procedure: physical therapy||Phase 2|
OBJECTIVES: I. Determine the effect of megestrol and progressive resistance training on lean body mass, total body weight, functional capacity, appetite, and fatigue in patients with weight loss due to advanced malignancy.
OUTLINE: This is a multicenter study. Patients receive oral megestrol once daily. Patients also begin progressive resistance training 3 days a week. Treatment/exercise continues for 12 weeks in the absence of unacceptable toxicity or progressive weight loss (greater than 5 pounds or 5% or more over first 4 study weeks).
PROJECTED ACCRUAL: A total of 46 patients will be accrued for this study within 1 year.
|Study Type :||Interventional (Clinical Trial)|
|Primary Purpose:||Supportive Care|
|Official Title:||Phase II Trial of Progressive Resistance Training With Megestrol Acetate for the Treatment of Cancer-Related Weight Loss|
|Study Start Date :||January 2000|
|Primary Completion Date :||November 2003|
|Study Completion Date :||November 2003|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004912
|United States, Arkansas|
|University of Arkansas - Department of Geriatrics|
|North Little Rock, Arkansas, United States, 72114-1706|
|United States, California|
|Pacific Shores Medical Group|
|Long Beach, California, United States, 90813|
|United States, Florida|
|Shands Hospital and Clinics, University of Florida|
|Gainesville, Florida, United States, 32610-100277|
|United States, Illinois|
|Robert H. Lurie Comprehensive Cancer Center, Northwestern University|
|Chicago, Illinois, United States, 60611-3013|
|Office of David Cella|
|Evanston, Illinois, United States, 60201|
|United States, North Carolina|
|Raleigh, North Carolina, United States, 27607|
|Study Chair:||Jamie Hayden Von Roenn, MD||Robert H. Lurie Cancer Center|